GENFLEET-B

2595
19.34010.79% ( -2.340 )
Delay Closed: Nov 16, 16:08:11

Overview

GENFLEET-B (2595)

GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases...

Open
21.680
High
21.880
Low
19.070
Prev. Close
21.680
Volume
3.71M
Turnover
73.48M
Avg Price
19.798
Bid/Ask Ratio
-60.00%
Amplitude
12.96%
52wk High
52.900
Volume Ratio
1.56
Turnover Ratio
1.07%
52wk Low
17.580
HK Mkt Cap
6.74B
Market CapHKD
7.36B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-3.98
EPSDynamic
-1.33
EPSStatic
--
BVPS
4.86
P/B
3.98
HK Shares
348.46M
Dividend YieldTTM
--
DividendTTM
--
Shares
380.80M
Min lot size
200
Currency
HKD

GENFLEET-B Analyst Rating

View more

Forecast & Rating

Oct 15, 2026
Price forecast
HK$50.91163.23%
Forecast & RatingStrong buy
5analysts
  • Strong buy80.00%
  • Buy20.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    GenFleet Therapeutics (2595.HK) spiked to HK$21.36 at 09:32 BJ, then fell steadily through the session to close at HK$19.14, down about 11.7% from the prior HK$21.68, settling near the afternoon low of HK$19.07 at 15:50 and below the HK$19.80 full-day average price, a spike-and-fade pattern on 3.70 million shares. The stock had risen 12% in a single session when its GFH276 combination therapies won China clinical clearance and has since given that gain back; multiple brokers rate it buy and the company has filed next-day share-buyback returns repeatedly, neither of which held the price. Q2 2026 revenue was HK$24.53 million, down 49.55% year on year, while the net loss of HK$127.15 million narrowed 66.78% and loss per share of HK$0.3433 improved 76.8%; an operating loss of HK$113.82 million, however, widened 137.24%, so shrinking revenue alongside a larger operating loss frames the pressure. Narrowing losses and the buyback record remain the few supports of the day.

  2. Nov, 13

    GenFleet Therapeutics-B staged a spike-and-fade session, opening at the day's high of HK$23.82 before sliding one-way to HK$21.20 at 14:42 BJ and closing at HK$21.44, about 10% below the prior close of HK$23.82, on HK$61.65 million turnover and a thin 0.80% turnover rate. The move follows a 12% single-day jump driven by China trial approvals for GFH276 combination therapies and a 41.1% response rate in an early-stage pancreatic cancer study, plus more than half a dozen share-buyback next-day disclosure returns since late October; with no fresh announcement today, those gains met profit-taking. Fundamentals remain at an early commercial scale: Q2 2026 revenue was HK$24.53 million, down 49.55% year on year, while the net loss of HK$127.15 million narrowed 66.78% and loss per share of HK$0.3433 narrowed 76.8%, though the operating loss of HK$113.82 million widened 137.24%. The stock sits below MA20 of HK$24.98 and MA60 of HK$27.73, down 4.03% year to date, 59.47% under the April 26 52-week high of HK$52.90 yet 21.96% above the November 2 low of HK$17.58, with PB at 4.42x. While continued buyback disclosures may offer some support.

  3. Nov, 10

    GenFleet Therapeutics-B rose 6.4% to HK$23.96, driven by China clinical trial approvals for multiple combination therapies involving its oral pan-RAS inhibitor GFH276 and by the company's Nov 6 buyback of 220,000 shares for HK$4.86 million. The session traced a dip-and-recover pattern before fading into the close: it touched HK$22.88 in the morning, reached HK$24.40 in the afternoon, then settled at HK$23.96 on HK$39.99 million turnover. Orient Securities and China Universal each added 299,600 shares at about HK$23.44. Despite the rebound, the price remains below its 20-day moving average of HK$25.54 and 60-day MA of HK$28.11, 54.71% below the 52-week high of HK$52.90 and 36.29% above the Nov 2 low of HK$17.58, with a year-to-date gain of 7.25%. Q2 revenue was HK$24.53 million, down 49.55% year on year; net loss narrowed 66.78% to HK$127.15 million while operating loss widened 137.24% to HK$113.82 million. The stock's PB stands at 4.94. Though the clinical and buyback news supported the move, the revenue decline and wider operating loss remain in contrast with the rebound.

  4. Nov, 9

    GenFleet Therapeutics-B opened 7.3% higher at HK$23.40 but faded to close at HK$22.52, up 3.30%, as the company repurchased 220,000 H shares for HK$4.86 million on 6 November, taking cumulative buybacks to 2.9078 million H shares, while its oral pan-RAS inhibitor GFH276 won mainland China trial approvals for multiple combination studies. Second-quarter revenue fell 49.55% year on year to HK$24.53 million; the HK$127.2 million net loss narrowed 66.78%, yet the operating loss widened 137% to HK$113.8 million. The stock is up just 0.81% year to date and sits 57.43% below its 52-week high of HK$52.90, closing under both the MA20 of HK$25.73 and MA60 of HK$28.22. Though the bid rests largely on buybacks and clinical progress, the revenue contraction has yet to turn.

  5. Nov, 6

    Genfleet Therapeutics-B fell 8.33% to HK$21.80 in a high-open, low-close session, fading from an intraday peak of HK$23.02 at 09:40 BJ to a HK$21.68 low at 15:46 BJ on 1.945 million shares, extending the prior session's roughly 7% decline as the market kept unwinding the 12% surge sparked by China trial approvals for multiple GFH276 pan-RAS inhibitor combination therapies. Fundamentals cut both ways: Q2 2026 revenue of HK$24.5 million fell 49.55% year on year and the HK$127.2 million net loss narrowed 66.78%, yet the operating loss widened 137.24%, with ROE at -27.42% and PB at 4.49. Buybacks of 551,000 shares for about HK$11.25 million on 2-3 November, plus separate 299,600-share stake increases by Orient Securities and China Universal Asset Management at roughly HK$23.44, sit above the current price. The stock is 58.79% below its 26 April high of HK$52.90, only 24% above the 2 November 52-week low of HK$17.58, and below its MA20 of HK$26.03 and MA60 of HK$28.37; the narrowing loss and steady buybacks offer some offset, though.

News

Bullish vs. Bearish — Last 3 Months

11.4k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    momoM

    $GENFLEET-B(02595.HK) The recent Longbridge lottery rate is acceptable 😌

    momoM 2025-09-1717:22:10 认购股数80000股 中签200股 劲方医药-B02595 价值4,078 HKD New shares